NCT00387933View on ClinicalTrials.gov

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

PHASE1CompletedINTERVENTIONAL

Enrollment

37

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

January 31, 2009

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG

hydroxyurea

DRUG

imatinib mesylate

DRUG

vatalanib

Trial Locations (1)

27710

Duke Comprehensive Cancer Center, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Duke University

OTHER

NCT00387933 - Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma | Biotech Hunter | Biotech Hunter